Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
6 versus 12 months of adjuvant trastuzumab for HER2-posit... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
0
Authors
Luke Hughes‐Davies
92 more
Luke Hughes‐Davies
•
Adrian Harnett
90 more
•
Daniela Lee
Published
June 1, 2019
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to review
Share your thoughts on this paper...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet
Topics
Medicine
Cancer Oncology
Internal Medicine
Surgery
Radiology, Nuclear Medicine And Imaging
Show all topics
DOI
10.1016/s0140-6736(19)30650-6
License
CC-BY
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet
Topics
Medicine
Cancer Oncology
Internal Medicine
Surgery
Radiology, Nuclear Medicine And Imaging
Show all topics
DOI
10.1016/s0140-6736(19)30650-6
License
CC-BY
Other Formats
PDF
